Retsef Levi's role in reviewing Covid-19 vaccine safety drew scrutiny ahead of a March 2026 meeting of the federal Advisory Committee on Immunization Practices. The dispute centered on whether his published work supports the conclusions attached to it, not on a newly announced federal vaccine restriction.
Levi, an MIT operations management professor appointed to ACIP by Health Secretary Robert F. Kennedy Jr., led the committee's special immunizations work group on Covid-19 vaccines. The Guardian reported that more than a dozen scientists and public-health experts criticized research he had authored or co-authored.
Critics Focused on Study Design and Interpretation
One disputed paper used Israeli emergency-call data to examine cardiac-arrest and acute-coronary-syndrome calls among people ages 16 to 39. Critics argued that its design could identify correlations but could not separate vaccination effects from Covid-19 infections or establish that vaccination caused the reported pattern.
Levi told FactCheck.org in 2022 that the findings showed correlation, not causation, and called for more research. Scientific Reports investigated the paper, required a correction covering several errors and did not retract it.
The Guardian also described criticism of a non-peer-reviewed paper co-authored by Levi and Florida Surgeon General Joseph Ladapo. That analysis compared all-cause mortality among recipients of Pfizer and Moderna Covid-19 vaccines. Experts consulted by the newspaper said missing information about pre-existing health conditions made the result difficult to interpret.
Those objections matter because an advisory committee must distinguish a safety signal that deserves investigation from evidence strong enough to change a recommendation. A correlation can justify a better-designed study; it cannot by itself establish the cause of an illness or death.
Levi and HHS Rejected the Criticism
Levi said his papers were factual, balanced and rigorous, and that criticism of his work had been addressed through formal peer-review processes. He also cited more than two decades of work on analytical methods, healthcare risk-benefit decisions, biologics manufacturing, pharmacovigilance and drug safety.
HHS told the Guardian that attacks on Levi were politically motivated and ignored his credentials. The department said Kennedy had selected ACIP members willing to ask difficult questions and follow evidence rather than automatically approve recommendations.
The disagreement therefore was not whether vaccine safety should be reviewed. It was whether the committee's methods, evidence standards and handling of uncertainty would be strong enough to produce credible conclusions.
The March Agenda Was Narrower Than the Predictions
As of March 10, the published agenda for ACIP's March 18-19 meeting included Covid-19 vaccine injuries, long Covid and possible changes to the way vaccine recommendations are developed. The agenda did not establish that the committee would restrict childhood schedules, limit government-funded vaccination or adopt policies used by particular states.
Neither report documented executive orders removing vaccine-manufacturer liability protections or bills advancing through Congress. Those actions cannot be presented as decisions simply because personnel and advisory priorities were changing.
STAT reported a separate personnel development at the FDA: Vinay Prasad, director of the Center for Biologics Evaluation and Research, was expected to leave after a series of controversial decisions involving rare-disease drugs. The publicly accessible report did not establish that Kennedy had chosen Prasad's replacement or that the vacancy would be used to install a political loyalist.
Evidence Standards Are the Real Test
The strongest criticism of this appointment is methodological, not theatrical. Levi's position gives him influence over how safety claims are framed and tested. That makes transparent protocols, public data, appropriate comparison groups and clear separation of correlation from causation essential.
HHS is entitled to defend its appointee, and Levi is entitled to answer his critics. Neither defense resolves the underlying statistical questions. The credible response is to show how the committee evaluates competing explanations, weighs benefits against risks and changes a recommendation only when the evidence supports the change.
Predictions of inevitable outbreaks, deaths or the collapse of modern medicine go beyond the two reports available on March 10. The immediate accountability test is more concrete: whether ACIP publishes evidence and reasoning that independent specialists can examine. If a safety review begins with a fixed conclusion or relies on designs that cannot answer causal questions, public trust will not be restored by calling the process transparent.